There has been a steady shift in private payer market, with expanded coverage being offered for obesity management drugs, like smoking cessation drugs before it. Some GLP-1s or diabetes drugs are also being considered for use due their potential to promote weight loss.

This raises questions important questions for our panelists to discuss; appropriate use, and whether access to these costly drugs will be sustainable moving forward, as demand grows.